Tag

James D. Brenton is a senior group leader at the Cancer Research UK (CR-UK) Cambridge Institute and leads the Functional Genomics of Ovarian Cancer laboratory. He qualified in medicine from University College London in 1988 and trained in medical oncology at the Royal Marsden Hospital, Princess Margaret Hospital, Toronto and the Department of Oncology, University of Cambridge. He has been an honorary consultant in medical oncology at Cambridge University Hospitals NHS Foundation Trust since 2001. His PhD work was carried out at the Wellcome Trust/Cancer Research UK Gurdon Institute of Cancer and Developmental Biology and he held a Cancer Research UK Senior Clinical Research Fellow from 2001–2006 at the Hutchison/MRC Research Centre.

His research focuses on the identification of prognostic and predictive markers for therapy in ovarian cancer and identifying mechanisms of drug resistance, with particular emphasis on the genomic profiling of clinical samples and bioinformatic analysis.

He is the chair of the Informatics Advisory Group for the national CR-UK Stratified Medicine Programme and was previously Vice-Chair of the CR-UK Biomarkers and Imaging Discovery and Development Committee. He is a member of the international Ovarian Tumor Tissue Analysis (OTTA) Consortium project approval committee, the SGCTG Protocol Review Committee, NCRI ovarian cancer subgroup and the CR-UK Clinical Fellows Mentor Panel.

Dr. Balakrishna Naik , MBBS, MD, D.G.O,Senior Consultant,Obstetrician and Gynecologist at NH Multispecialty Hospital, Bangalore,India.

The Eve Appeal is a registered charity, formed in 2005. Since then, we have worked hard to raise money to fund the world-class research programme at the Department of Women's Cancer based at University College London (UCL).

The Department's vital and much-needed research will benefit women in the UK and worldwide.

A report by an independent panel reviewing the Department's work and progress (the Pattison Review Report 2009) acknowledges the importance of The Eve Appeal's role: "The Eve Appeal has consistently contributed about 15% of the total research income. However, its contributions have been disproportionately important because they have pump-primed new projects, supported highly innovative work and covered gaps in funding allowing projects to maintain momentum. The national and international standing of the projects to which it has contributed is testament to the effectiveness of The Eve Appeal support."

Major breakthroughs are already being achieved towards improving survival rates of women with gynaecological cancers through the Department's pioneering research into screening, early diagnosis and risk prediction. To build on these successes and save women's lives, raising urgent and on-going funds is critical.

Promoting awareness is vital too. The Eve Appeal therefore disseminates information about the research we fund. We publicise - and provide information on - gynaecological cancers. We contribute to the development of policy and campaigns. And we work in partnership with others to improve the healthcare and support of women.